Drugs / HRO350
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06125808 | May 2023 → Oct 2024 | psoriasis | Arctic Bioscience | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRO350 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06125808 ↗ |
| Modality | Other / unclassified | “HRO350 contains an oil-based extract from herring roe (Clupea harengus) in soft capsules” NCT06125808 ↗ |
| Route | Oral | “Daily treatment will begin with 3 capsules of either HRO350 or placebo taken in the morning and 3 capsules of either HRO350 or placebo taken in the evening for up to 52 weeks.” NCT06125808 ↗ |